Company Filing History:
Years Active: 2006
Title: David Hurst - Innovator in HSP90-Inhibitors
Introduction
David Hurst is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins involved in cancer progression.
Latest Patents
Hurst holds a patent for "Pyrazolopyrimidines and related analogs as HSP90-inhibitors." This patent describes a compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt, or prodrug thereof. This innovation is crucial for advancing cancer treatment options.
Career Highlights
David Hurst is currently associated with Conforma Therapeutics Corporation, where he continues to work on groundbreaking research and development in the pharmaceutical industry. His expertise in medicinal chemistry has positioned him as a valuable asset in the quest for effective cancer therapies.
Collaborations
Hurst has collaborated with esteemed colleagues such as Srinivas Rao Kasibhatla and Marco Antonio Biamonte. These partnerships have fostered a collaborative environment that enhances the innovation process and accelerates the development of new therapeutic solutions.
Conclusion
David Hurst's work in developing HSP90-inhibitors exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions are paving the way for advancements in cancer treatment, showcasing the importance of research and collaboration in the field.